外周血SEPTIN9基因甲基化检测在结直肠癌诊断中的研究进展*

doi:10.3969/j.issn.1671-2587.2021.02.028

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (2): 263-268.DOI: 10.3969/j.issn.1671-2587.2021.02.028

外周血SEPTIN9基因甲基化检测在结直肠癌诊断中的研究进展^*

宫媛, 王卫华, 杜海涛, 吕昆明, 常青, 万军

100853 北京,中国人民解放军总医院第二医学中心消化内科

收稿日期:2020-05-29 出版日期:2021-04-20 发布日期:2021-04-19
通讯作者: 万军,男,主任医师,教授,主要从事消化道肿瘤、干细胞移植和炎症性肠病的基础和临床研究,（E-mail）wanjun301@126.com。共同通信作者：常青,女,副主任医师,主要从事消化道肿瘤和干细胞移植的相关研究,（E-mail）evergreenchq@sina.com。
作者简介:宫媛（1979-）,女,山东威海人,副主任医师,博士,主要从事消化道肿瘤和干细胞移植的基础和临床研究,（E-mail）gongquanquan79@163.com。
基金资助:
*本课题受解放军总医院第二医学中心保健专项科研课题（No.NLBJ-2019003）资助

Received:2020-05-29 Online:2021-04-20 Published:2021-04-19

摘要/Abstract

摘要： 结直肠癌（CRC）是消化系统最常见的恶性肿瘤之一,早期筛查及诊断至关重要。SEPTIN9 基因甲基化（mSEPT9）与CRC 发生发展密切相关,外周血mSEPT9检测可指导CRC临床分期,预测CRC术后复发和治疗效果,适合于对易感人群进行CRC筛查。mSEPT9对含有绒毛成分和异型增生的腺瘤、息肉的诊断价值优于未含绒毛成分和异型增生的腺瘤、息肉。mSEPT9的含量和检测受很多因素影响。本文对SEPTIN9基因甲基化在CRC诊断的价值和最新研究进展进行综述。

关键词: 血浆, SEPTIN9基因, DNA甲基化, 结直肠癌

中图分类号:

R735.3

宫媛, 王卫华, 杜海涛, 吕昆明, 常青, 万军. 外周血SEPTIN9基因甲基化检测在结直肠癌诊断中的研究进展^*[J]. 临床输血与检验, 2021, 23(2): 263-268.

参考文献

[1] ALONSO-ABREU I,ALARCÓN-FERNÁNDEZ O,GIMENO-GARCÍA A Z,et al.Early colonoscopy improves the outcome of patients with symptomatic colorectal cancer[J].Dis Colon Rectum,2017,60(8):837-844.
[2] ZENG Y Q,CAO Y,LIU L,et al.SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation[J].Cell Death Dis,2019,10(10):720.
[3] BEHROUZ SHARIF S,HASHEMZADEH S,MOUSAVI ARDEHAIE R,et al.Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker[J].Oncol Lett,2016,12(6):5335-5343.
[4] SUN J,FEI F,ZHANG M Q,et al.The role of mSEPT9 in screening,diagnosis,and recurrence monitoring of colorectal cancer[J].BMC Cancer,2019,19(1):450.
[5] CHEN Y,WANG Z Z,ZHAO G D,et al.Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test[J].Dis Markers,2019,2019:5232780.
[6] 贺娜,吴开春.血浆甲基化septin9基因与结直肠癌相关性的研究进展[J].中华消化杂志,2015,35(5):358-360.
[7] LIN K W.mSEPT9 (epi proColon) blood test for colorect al cancer screening[J].Am Fam Physician,2019,100(1):10-11.
[8] XIE L,JIANG X Y,LI Q,et al.Diagnostic value of methylated Septin9 for colorectal cancer detection[J].Front Oncol,2018,8:247.
[9] LAMB Y N,DHILLON S.Epi proColon^® 2.0 CE:a blood-based screening test for colorectal cancer[J].Mol Diagn Ther,2017,21(2):225-232.
[10] CHURCH T R,WANDELL M,LOFTON-DAY C,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J].Gut,2014,63(2):317-325.
[11] NIAN J Y,SUN X,MING S Y,et al.Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection:a systematic review and meta-analysis[J].Clin Transl Gastroenterol,2017,8(1):e216.
[12] ØRNTOFT M B,NIELSEN H J,ØRNTOFT T F,et al.Performance of the colorectal cancer screening marker Sept9 is influenced by age,diabetes and arthritis:a nested case-control study[J].BMC Cancer,2015,15:819.
[13] ZORZI M,SENORE C,DA RE F,et al.Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy)[J].Gut,2015,64(9):1389-1396.
[14] SONG L L,LI Y M.Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years[J].Biomark Med,2017,11(6):415-418.
[15] JIN P,KANG Q,WANG X,et al.Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm[J].J Gastroenterol Hepatol,2015,30(5):830-833.
[16] WU D,ZHOU G P,JIN P,et al.Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening[J].J Mol Diagn,2016,18(4):535-545.
[17] 中华医学会消化内镜学分会,中国抗癌协会肿瘤内镜学专业委员会.中国早期结直肠癌筛查及内镜诊治指南(2014,北京)[J].中华医学杂志,2015,95(28): 2235-2252.
[18] WANG Y,CHEN P M,LIU R B.Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection[J].World J Gastrointest Oncol,2018,10(1):15-22.
[19] JOHNSON D A,BARCLAY R L,MERGENER K,et al.Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study[J].PLoS One,2014,9(6):e98238.
[20] SONG L L,YU H T,JIA J,et al.A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening,monitoring,diagnosis and prognosis[J].Cancer Biomark,2017,18(4):425-432.
[21] LI B,GAN A,CHEN X,et al.Diagnostic performance of DNA hypermethylation markers in peripheral blood for the detection of colorectal cancer:a meta-analysis and systematic review[J].PLoS One,2016,11(5):e0155095.
[22] SUN G P,MENG J,DUAN H,et al.Diagnostic assessment of septin9 DNA methylation for colorectal cancer using blood detection: a meta-analysis[J].Pathol Oncol Res,2019,25(4):1525-1534.
[23] SONG L L,JIA J,PENG X M,et al.The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests:a meta-analysis[J].Sci Rep,2017,7(1):3032.
[24] SONG L L,PENG X M,LI Y M,et al.The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening[J].Epigenomics,2017,9(5):599-610.
[25] POTTER N T,HURBAN P,WHITE M N,et al.Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma[J].Clin Chem,2014,60(9):1183-1191.
[26] MA Z Y,LAW W L,NG E K O,et al.Methylated septin 9 and carcinoembryonic antigen for serological diagnosis and monitoring of patients with colorectal cancer after surgery[J].Sci Rep,2019,9(1):10326.
[27] HE N,SONG L L,KANG Q,et al.The pathological features of colorectal cancer determine the detection performance on blood ctDNA[J].Technol Cancer Res Treat,2018,17:1533033818791794.
[28] SONG L,LI Y,JIA J,et al.Algorithm optimization in methylation detection with multiple RT-qPCR[J].PLoS One,2016,11(11):e0163333.
[29] SONG L L,GUO S H,WANG J Y,et al.The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer[J].Biomark Med,2018,12(9):961-973.
[30] FU B,YAN P,ZHANG S,et al.Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer[J].Dis Markers,2018,2018: 6437104.
[31] SONG L L,LI Y M.SEPT9:a specific circulating biomarker for colorectal cancer[J].Adv Clin Chem,2015,72:171-204.
[32] THAM C,CHEW M,SOONG R,et al.Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer[J].Cancer,2014,120(20):3131-3141.
[33] KEATING S T,EL-OSTA A,EL-OSTA A.Epigenetics and metabolism[J].Circ Res,2015,116(4):715-736.
[34] TÓTH K,PATAI Á V,KALMÁR A,et al.Circadian rhythm of methylated septin 9,cell-free DNA amount and tumor markers in colorectal cancer patients[J].Pathol Oncol Res,2017,23(3):699-706.
[35] ZHU H,BHAGATWALA J,HUANG Y,et al.Race/ethnicity-specific association of vitamin D and global DNA methylation: cross-sectional and interventional findings[J].PLoS One,2016,11(4):e0152849.
[36] ZHANG M,HE Y,ZHANG X,et al.A pooled analysis of the diagnostic efficacy of plasmic methylated septin-9 as a novel biomarker for colorectal cancer[J].Biomed Rep,2017,7(4):353-360.
[37] YANG X,XU Z J,CHEN X,et al.Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients[J].World J Gastroenterol,2019,25(17): 2099-2109.

外周血SEPTIN9基因甲基化检测在结直肠癌诊断中的研究进展^*

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	林放, 周谋, 单桂秋, 李艳辉, 李文丹. 不同来源复水液对冻干PRP活化和释放生长因子影响的比较^*[J]. 临床输血与检验, 2021, 23(2): 142-145.
[2]	张媛媛, 应美爱, 潘健, 刘洪涛, 刘潜, 戴帅, 王慧茹, 刘会兰. 血浆置换在ABO血型不相容的亲属活体肾移植中应用效果评价^*[J]. 临床输血与检验, 2021, 23(2): 167-172.
[3]	冯子阳, 查占山, 周载鑫, 唐河山, 余咏潮, 钱宝华. 一例血浆置换在马凡综合征患者术后并发血栓性血小板减少性紫癜治疗中的应用[J]. 临床输血与检验, 2021, 23(2): 242-245.
[4]	黄佳丽, 刘正婷, 陈尚良, 周义文. 亚甲蓝光病毒灭活血浆的研究进展^*[J]. 临床输血与检验, 2021, 23(2): 268-272.
[5]	王伟, 奚铭远, 程晨, 许珍珍, 骆群. 血浆置换救治稀料中毒1例[J]. 临床输血与检验, 2021, 23(1): 107-108.
[6]	王娟, 王文婷, 胡兴斌, 尹文. 血浆置换成功治疗难治性莫旺综合征合并膜性肾病1例[J]. 临床输血与检验, 2021, 23(1): 109-111.
[7]	王瑞含, 范金波, 周国均, 王飞, 刘久波. PRP治疗膝骨关节炎的临床应用研究进展[J]. 临床输血与检验, 2020, 22(6): 659-663.
[8]	邱艳, 王雪珩, 吴涛. 新发传染病康复者血浆疗法应用现状及研究进展[J]. 临床输血与检验, 2020, 22(5): 449-454.
[9]	唐宗生. 强化新冠肺炎康复者恢复期血浆捐献照护的策略及其意义[J]. 临床输血与检验, 2020, 22(5): 458-461.
[10]	赵鸿雁, 刘更夫, 黄懋雯, 梅方超. 重症新冠肺炎患者输注新冠恢复期血浆的免疫学相关指标变化[J]. 临床输血与检验, 2020, 22(5): 462-466.
[11]	庄远, 汪德清. 传统血浆置换治疗如何适应现代医学的发展[J]. 临床输血与检验, 2020, 22(5): 472-476.
[12]	余凤秀, 李津杞, 朱燕霞, 郭菲, 周载鑫, 顾海慧, 钱宝华. 二次重度离心制备法对冷沉淀凝血因子质量的影响^*[J]. 临床输血与检验, 2020, 22(5): 477-480.
[13]	朱鑫方, 王苑, 杜丹心, 夏荣. 康复者恢复期血浆在病毒性疾病治疗中的研究进展[J]. 临床输血与检验, 2020, 22(4): 337-342.
[14]	谢毓滨, 邹彬彬, 陈东, 阳智芬, 谭智文, 王清, 旷开其, 晏永和. 新冠恢复期血浆拟捐献者健康评估及抗体水平分析[J]. 临床输血与检验, 2020, 22(4): 343-348.
[15]	洪缨. COVID-19康复者恢复期血浆采集和使用[J]. 临床输血与检验, 2020, 22(4): 349-354.